We are live on ! Find out more
PRQR icon

ProQR Therapeutics

51 hedge funds and large institutions have $299M invested in ProQR Therapeutics in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more capital invested

Capital invested by funds: $125M → $299M (+$174M)

133% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 9

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

47% more call options, than puts

Call options by funds: $22K | Put options by funds: $15K

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

5.34% more ownership

Funds ownership: 55.73%61.07% (+5.3%)

2% more funds holding

Funds holding: 5051 (+1)

Holders
51
Holders Change
+1
Holders Change %
+2%
% of All Funds
1%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
17
Increased
21
Reduced
9
Closed
15
Calls
$22K
Puts
$15K
Net Calls
+$7K
Net Calls Change
+$7K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$54.5M +$37.3M +4,790,532 +680%
RI
2
RTW Investments
New York
$47.4M +$8.4M +1,078,302 +29%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$45.3M +$6.51M +835,812 +22%
Goldman Sachs
4
Goldman Sachs
New York
$33.2M +$219K +28,085 +0.8%
Jennison Associates
5
Jennison Associates
New York
$26.1M +$90.5K +11,614 +0.4%
ACM
6
Aquilo Capital Management
California
$19.1M +$8.5M +1,090,909 +131%
AG
7
Artal Group
Luxembourg
$12.9M
Fidelity Investments
8
Fidelity Investments
Massachusetts
$11.7M +$3.13M +401,300 +52%
DCM
9
DAFNA Capital Management
California
$11M +$6.64M +852,479 +326%
SFM
10
Sphera Funds Management
Israel
$7.98M -$857K -110,000 -12%
UBS Group
11
UBS Group
Switzerland
$5.03M +$438K +56,193 +12%
BlackRock
12
BlackRock
New York
$4.61M -$2.59M -332,566 -42%
KA
13
Kerrisdale Advisers
Florida
$4.45M -$130K -16,700 -4%
Millennium Management
14
Millennium Management
New York
$3.4M +$939K +120,567 +54%
AGA
15
Altrinsic Global Advisors
Connecticut
$2.19M +$156K +20,000 +10%
CAC
16
Cowen and Company
New York
$1.03M +$808K +103,727 New
Allianz Asset Management
17
Allianz Asset Management
Germany
$953K +$506K +64,945 +209%
Renaissance Technologies
18
Renaissance Technologies
New York
$823K -$150K -19,300 -19%
OAM
19
Oxford Asset Management
United Kingdom
$786K +$119K +15,253 +24%
FSA
20
Franklin Street Advisors
North Carolina
$595K
HF
21
HRT Financial
New York
$561K +$441K +56,682 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$525K +$184K +23,560 +80%
Fidelity International
23
Fidelity International
Bermuda
$518K +$93.5K +12,009 +30%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$506K +$397K +50,990 New
JP Morgan Chase
25
JP Morgan Chase
New York
$505K +$397K +51,014 New

PRQR Hedge Fund Activity: Q4 2019 in Review

51 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2019, worth a combined $299M — up 139% from $125M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PRQR positions and 15 closed out — a net gain of 2 holders — while 21 added to existing stakes and 9 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $37.3M. The largest seller was BlackRock, cutting an estimated $2.59M.

  • 51 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2019, up from 50 in Q3 2019.
  • Funds reported $299M of ProQR Therapeutics stock for Q4 2019, up 139% quarter-over-quarter.
  • 17 funds opened new ProQR Therapeutics positions in Q4 2019 and 15 closed out, a net change of +2 holders.
  • The largest ProQR Therapeutics buyer in Q4 2019 was Wellington Management Group, an estimated $37.3M added.
  • The largest ProQR Therapeutics seller in Q4 2019 was BlackRock, an estimated $2.59M sold.

Based on aggregated 13F filings for Q4 2019.